1.
Perspectives in cholesterol-lowering therapy: the role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption.
Bruckert, E, Giral, P, Tellier, P
Circulation. 2003;(25):3124-8
2.
A subtherapeutic international normalized ratio despite increasing doses of warfarin: could this be malabsorption?
Lara, LF, Delgado, LL, Frazee, LA, Haupt, KM, Rutecki, GW
The American journal of the medical sciences. 2000;(3):214-8
Abstract
OBJECTIVE To describe a case of warfarin resistance apparently caused by malabsorption and to review the literature regarding warfarin resistance. CASE SUMMARY A 28-year-old renal transplant patient with systemic lupus erythematosus was admitted for upper extremity thrombophlebitis. Resistance to oral warfarin was demonstrated. Potential causes were investigated. The trapezoidal rule was used to compare the area under the curve for intravenous versus oral dosing of warfarin. The usual bioavailability of warfarin should be 100%. In this patient, warfarin bioavailability after oral dosing was 1.5%. Three potential causes, malabsorption (FF), enzymatic degradation (FG), and first-pass extraction in the portal circulation (FH), are discussed. CONCLUSION This case demonstrates resistance to warfarin presumably caused by malabsorption.